DBV TechnologiesDBVTF 27 9-Day RSI is 4.95 as of Jul. 06, 2026. GuruFocus rates DBVTF with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, DBV Technologies ranks better than 56.91% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
DBV Technologies 9-Day RSI Related Terms
DBVTF vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, DBV Technologies's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where DBV Technologies's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (DBVTF) has a 9-Day RSI of 4.95 as of Jul. 06, 2026. According to the industry distribution chart, DBV Technologies ranks #611 out of 1418 companies in the Biotechnology industry, placing it in the top 43.1%.
Is DBV Technologies' 9-Day RSI too high?
DBV Technologies' current 9-Day RSI is 4.95. The Biotechnology industry median 9-Day RSI is 53.71. DBV Technologies' value of 4.95 is 90.8% below this industry median. Based on the distribution chart, DBV Technologies ranks #611 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DBV Technologies has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #611 out of 1418 companies for 9-Day RSI. This puts DBV Technologies in the upper half of its industry. The industry median 9-Day RSI is 53.71. DBV Technologies' value of 4.95 is 90.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.71, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DBV Technologies's current 9-Day RSI of 4.95 is 90.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current 9-Day RSI is 4.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVTF) has a current 9-Day RSI of 4.95. The current 9-Day RSI is 4.95 and 90.8% below the Biotechnology industry median of 53.71. DBV Technologies' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For DBV Technologies (DBVTF), the current 9-Day RSI is 4.95 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
27GF Score
Get the complete analysis for DBVTF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVTF has been successfully added to your 